Eagle Pharmaceuticals (EGRX) Reports Prelim. 3Q EPS Above Consenus, Prelim. 3Q Revenues Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Reports Prelim. 3Q EPS Above Consenus, Prelim. 3Q Revenues Below Consensus

Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss

November 1, 2018 6:51 AM EDT

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.91, $0.07 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.23 million.

While we were disappointed in the outcome of the fulvestrant trial, we believe in the strength of the remaining products in our pipeline and... More

Eagle Pharmaceuticals (EGRX) Initiates $50M Accelerated Share Buyback as Part of New $150M Share Buyback Authorization

October 30, 2018 7:31 AM EDT

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated share repurchase (ASR) transaction with JPMorgan Chase Bank, National Association (JP Morgan) and (ii) up to $100 million in additional repurchases. This reflects the Company's conviction in its business strategy.

The specific... More